No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1–Infected Patients Receiving Antiretroviral Therapy
暂无分享,去创建一个
John W. Mellors | Robert W. Coombs | Michael M. Lederman | Lu Zheng | Ronald J. Bosch | M. Lederman | R. D’Aquila | J. Mellors | R. Bosch | D. Margolis | J. Eron | R. Gandhi | R. Coombs | Lu Zheng | Sarah W. Read | A. Wiegand | Joseph J. Eron | David M. Margolis | J. Jacobson | M. Kearney | R. D'Aquila | Ming Chang | Richard D'Aquila | Ann Wiegand | Rajesh T. Gandhi | Mary Kearney | Ellen S. Chan | Sarah Read | Beatrice Kallungal | Ming Chang | Erin A. Goecker | Jeffrey M. Jacobson | Mary F. Kearney | Beatrice A Kallungal | E. Goecker
[1] J Witek,et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. , 1999, JAMA.
[2] Joseph A Kovacs,et al. ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia , 2007, PLoS pathogens.
[3] J. Mellors,et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.
[4] Ron Milo,et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy , 2011, Nature.
[5] Sarah Palmer,et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects , 2010, Nature Medicine.
[6] Tara L. Kieffer,et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. , 2004, The Journal of infectious diseases.
[7] S. Lewin,et al. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? , 2011, AIDS.
[8] S J Gange,et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] Jeffrey N. Martin,et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. , 2003, The Journal of infectious diseases.
[10] Meei-Li W Huang,et al. Coamplified positive control detects inhibition of polymerase chain reactions , 1992, Journal of clinical microbiology.
[11] C. B. Hare,et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. , 2010, The Journal of infectious diseases.
[12] M. Lederman,et al. The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial , 2010, PLoS medicine.
[13] T. Calvez,et al. Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection , 2003, AIDS.
[14] D. Hazuda,et al. The Challenge of Finding a Cure for HIV Infection , 2009, Science.
[15] John L. Sullivan,et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.
[16] C. B. Hare,et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy , 2010, AIDS.
[17] Jeffrey N. Martin,et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. , 2011, The Journal of infectious diseases.
[18] Tara L. Kieffer,et al. Intrinsic Stability of Episomal Circles Formed during Human Immunodeficiency Virus Type 1 Replication , 2002, Journal of Virology.
[19] Connie Celum,et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. , 2007, The Journal of infectious diseases.